Alpha Profiles · Company Profile

ENANTA PHARMACEUTICALS INC

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/enanta-pharmaceuticals-inc

Entity: Public listing published
Primary listing: NASDAQ: ENTA
Verification: Partially verified
Last reviewed: 2026-09-06T06:04:21.326765+00:00

Overview

Alpha's canonical identity and public leadership record for ENANTA PHARMACEUTICALS INC.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

9 public records

Brendan Luu

Chief Business Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-022558Jan 26, 2026

Harry R. Trout

Vice President, Finance (Principal Financial Officer)

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-022558Jan 26, 2026

Jay R. Luly

President and Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-022558Jan 26, 2026

Jay R. Luly, Ph.D.

President and Chief Executive Officer and Director

State: confirmed
Effective: From Nov 19, 2025
Confidence: 94%
Evidence: ENTA 10-K executive officersNov 19, 2025

Kathleen S. Capps

Executive Director of Accounting, Controller

State: confirmed
Effective: From Nov 19, 2025
Confidence: 94%
Evidence: ENTA 10-K executive officersNov 19, 2025

Matthew P. Kowalsky

Chief Legal Officer and Corporate Secretary

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-022558Jan 26, 2026

Scott T. Rottinghaus

Chief Medical Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-022558Jan 26, 2026

Tara L. Kieffer

Chief Product Strategy Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-022558Jan 26, 2026

Yat Sun Or

Chief Scientific Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-022558Jan 26, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 6, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.